We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper.
- Authors
Saccardi, R; Freedman, M S; Sormani, M P; Atkins, H; Farge, D; Griffith, L M; Kraft, G; Mancardi, G L; Nash, R; Pasquini, M; Martin, R; Muraro, P A; European Blood and Marrow Transplantation Group; Center for International Blood and Marrow Research; HSCT in MS International Study Group
- Abstract
Haematopoietic stem cell transplantation (HSCT) has been tried in the last 15 years as a therapeutic option in patients with poor-prognosis autoimmune disease who do not respond to conventional treatments. Worldwide, more than 600 patients with multiple sclerosis (MS) have been treated with HSCT, most of them having been recruited in small, single-centre, phase 1-2 uncontrolled trials. Clinical and magnetic resonance imaging outcomes from case series reports or Registry-based analyses suggest that a major response is achieved in most patients; quality and duration of response are better in patients transplanted during the relapsing-remitting phase than in those in the secondary progressive stage.
- Publication
Multiple sclerosis (Houndmills, Basingstoke, England), 2012, Vol 18, Issue 6, p825
- ISSN
1477-0970
- Publication type
Journal Article
- DOI
10.1177/1352458512438454